Pulmonary Fibrosis Treatment Agents - Antifibrotic Therapy

The phrase "Pulmonary Fibrosis Treatment Agents - Antifibrotic Therapy" is a commercial formulary compendium category—specifically applied to pirfenidone—rather than a formal FDA-established pharmacologic class.

Clinically, these agents exert antifibrotic, anti-inflammatory, and antioxidant properties by downregulating pro-fibrotic growth factors and cytokines, notably transforming growth factor-beta (TGF-beta), thereby inhibiting fibroblast proliferation and collagen synthesis.

Their primary therapeutic role is to slow the decline of lung function and reduce disease progression in adults with idiopathic pulmonary fibrosis (IPF) and related progressive fibrosing interstitial lung diseases.